Cannabidivarin (CBDV) is a rare, non-psychoactive cannabinoid discovered in specific cannabis cultivars, especially those of Asian and African descent. Closely related to CBD but featuring a propyl side chain, CBDV has become a beacon of hope in cannabinoid science for its emerging potential in neurological health and rare epilepsy syndromes. As one of the new wave “gentle giants” of the cannabinoid world, CBDV’s star is rising in research and innovation.
CBDV’s molecular formula is C₁₉H₂₆O₂, with a molar mass of approximately 286.41 g/mol. Like THCV, CBDV features a three-carbon propyl side chain—this small difference from CBD creates unique interactions with biological systems. CBDV is classified as a neutral cannabinoid, typically appearing as a colorless oil, with a boiling point around 180 °C.
CBDV shows low direct affinity for CB₁ and CB₂ receptors but acts powerfully through modulation of TRP channels and neurotransmitter systems such as GABA and glutamate. It exhibits pronounced anticonvulsant, neuroprotective, and anti-inflammatory effects in preclinical research. CBDV’s mechanisms make it especially interesting for the treatment of epilepsy, neurodevelopmental disorders, and conditions involving abnormal neural signaling.
CBDV is being investigated as a potential breakthrough therapy for rare and drug-resistant forms of epilepsy, including Dravet and Lennox-Gastaut syndromes. Studies also explore its use in autism spectrum disorders, Rett syndrome, and muscular dystrophy. Unlike THC and even CBD, CBDV’s non-psychoactive nature and gentle receptor activity make it especially promising for pediatric applications.
CBDV remains rare in most cannabis strains, which limits its commercial availability and dosing consistency. Most clinical evidence is still in early stages; approved pharmaceutical forms are under development. CBDV is generally well-tolerated, with no significant psychoactive or intoxicating effects reported to date, but long-term safety data are still limited.
🛡️ Gentle Guardian — Neuroprotection — Epilepsy Breaker
👶 Child’s Shield — Non-psychoactive Clarity — Calmness
🌱 Silent Strength — Precision Balance — Support
Ongoing research explores CBDV for autism spectrum support, rare seizure disorders, Rett syndrome, and even as a future neurotherapeutic in degenerative or developmental conditions. Scientists are investigating its impact on neuroplasticity, synaptic stability, and muscular health.
CBDV stands as the gentle, emerging ally within the cannabinoid spectrum—marked by neuroprotection, anticonvulsant promise, and a vision for safer, more targeted therapies. As research advances, CBDV could reshape the future of cannabis-based medicine—especially for children and those most in need of novel treatments.
We never did this for the money.
We did it because molecules tell stories—stories that bridge healing, curiosity, and responsibility across cultures and generations.
If you feel this work holds value and wish to be part of sustaining independent research, you are warmly invited to stand with us.
🟢 Disclaimer
The information provided on this website is intended solely for general informational and educational purposes related to the scientific analysis and classification of medical cannabis data. It does not constitute medical advice, diagnosis, or treatment recommendations and should not be used as a substitute for professional medical consultation.
All content has been sourced from our proprietary database and is systematically processed, structured, and formatted through our middleware systems. A final validation is performed using a combination of algorithmic quality assurance procedures and editorial review.
While we strive to ensure the highest level of accuracy, completeness, and currency, we make no guarantees regarding the reliability or applicability of the information provided. For any questions related to health, treatment decisions, or the use of medical cannabis, please consult a qualified healthcare professional.
Maria-Theresia-Str. 11
81675 Munich
Germany
